menu
    • menu
    [{"orgOrder":0,"company":"Alteogen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"SOUTH KOREA","productType":"Enzyme","year":"2022","type":"Inapplicable","leadProduct":"ALT-BB4","moa":"Hyaluronic acid","graph1":"Undisclosed","graph2":"Phase I","graph3":"Alteogen","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Alteogen \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Alteogen \/ Undisclosed"},{"orgOrder":0,"company":"Alteogen","sponsor":"Daiichi Sankyo","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Antibody-drug Conjugate","year":"2024","type":"Licensing Agreement","leadProduct":"Trastuzumab Deruxtecan","moa":"Receptor protein-tyrosine kinase erbB-2 | DNA topoisomerase I","graph1":"Oncology","graph2":"Preclinical","graph3":"Alteogen","amount2":0.29999999999999999,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0.29999999999999999,"dosageForm":"Undisclosed","sponsorNew":"Alteogen \/ Daiichi Sankyo","highestDevelopmentStatusID":"4","companyTruncated":"Alteogen \/ Daiichi Sankyo"},{"orgOrder":0,"company":"Alteogen","sponsor":"Cristalia Produtos Quimicos Farma. Ltda","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"SOUTH KOREA","productType":"Undisclosed","year":"2017","type":"Inapplicable","leadProduct":"ALT02","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase I","graph3":"Alteogen","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Alteogen \/ Cristalia Produtos Quimicos Farma. Ltda","highestDevelopmentStatusID":"6","companyTruncated":"Alteogen \/ Cristalia Produtos Quimicos Farma. Ltda"},{"orgOrder":0,"company":"Alteogen","sponsor":"Intas Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Enzyme","year":"2021","type":"Collaboration","leadProduct":"ALT-B4","moa":"||Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Alteogen","amount2":0.11,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0.11,"dosageForm":"Injection","sponsorNew":"Alteogen \/ Intas Pharmaceuticals","highestDevelopmentStatusID":"3","companyTruncated":"Alteogen \/ Intas Pharmaceuticals"},{"orgOrder":0,"company":"Alteogen","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Enzyme","year":"2020","type":"Licensing Agreement","leadProduct":"ALT-B4","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Alteogen","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Alteogen \/ Undisclosed","highestDevelopmentStatusID":"3","companyTruncated":"Alteogen \/ Undisclosed"},{"orgOrder":0,"company":"Alteogen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Antibody-drug Conjugate","year":"2017","type":"Inapplicable","leadProduct":"ALT-P7","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Alteogen","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Alteogen \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Alteogen \/ Undisclosed"},{"orgOrder":0,"company":"Alteogen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Antibody-drug Conjugate","year":"2020","type":"Inapplicable","leadProduct":"ALT-P7","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Alteogen","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Alteogen \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Alteogen \/ Undisclosed"},{"orgOrder":0,"company":"Altos Biologics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"SOUTH KOREA","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"Aflibercept","moa":"Vascular endothelial growth factor A | Placenta growth factor","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Altos Biologics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Altos Biologics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Altos Biologics \/ Undisclosed"},{"orgOrder":0,"company":"Altos Biologics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"SOUTH KOREA","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"Aflibercept","moa":"Vascular endothelial growth factor A | Placenta growth factor","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Altos Biologics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Altos Biologics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Altos Biologics \/ Undisclosed"},{"orgOrder":0,"company":"Alteogen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"SOUTH KOREA","productType":"Cell & Gene Therapy","year":"2019","type":"Inapplicable","leadProduct":"ALT-L9","moa":"VEGF-A receptor","graph1":"Ophthalmology","graph2":"Phase I","graph3":"Alteogen","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Alteogen \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Alteogen \/ Undisclosed"},{"orgOrder":0,"company":"Alteogen","sponsor":"Sandoz B2B","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"SOUTH KOREA","productType":"Undisclosed","year":"2023","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Technology","graph2":"Undisclosed","graph3":"Alteogen","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Alteogen \/ Sandoz B2B","highestDevelopmentStatusID":"1","companyTruncated":"Alteogen \/ Sandoz B2B"},{"orgOrder":0,"company":"Alteogen","sponsor":"AstraZeneca","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Undisclosed","year":"2025","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Alteogen","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Alteogen \/ AstraZeneca","highestDevelopmentStatusID":"3","companyTruncated":"Alteogen \/ AstraZeneca"},{"orgOrder":0,"company":"Alteogen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"SOUTH KOREA","productType":"Protein","year":"2025","type":"Inapplicable","leadProduct":"Aflibercept","moa":"VEGF-A | PlGF","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Alteogen","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Alteogen \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Alteogen \/ Undisclosed"}]

    Find Clinical Drug Pipeline Developments & Deals by Alteogen

    Menu

    Alteogen

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    REF. STANDARDS & IMPURITIES

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Alteogen

                            South Korea arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Alteogen

                            South Korea arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Aflibercept

                            Therapeutic Area : Ophthalmology

                            Study Phase : Approved FDF

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Alteogen Gets EU Nod for Aflibercept Biosimilar EYLUXVI (ALT-L9)

                            Details : Eyluxvi (aflibercept) is indicated for the treatment of patients with neovascular (wet) age-related macular degeneration.

                            Product Name : Eyluxvi

                            Product Type : Protein

                            Upfront Cash : Inapplicable

                            September 17, 2025

                            Lead Product(s) : Aflibercept

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Approved FDF

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Alteogen

                            South Korea arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Alteogen

                            South Korea arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Study Phase : Discovery Platform

                            Sponsor : AstraZeneca

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            AstraZeneca, Alteogen Sign Deal for Subcutaneous Oncology Formulations

                            Details : AstraZeneca will acquire rights to use ALT-B4 to develop and commercialise subcutaneous formulations of oncology assets. Alteogen will be responsible for the commercial supply to AstraZeneca.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Undisclosed

                            March 17, 2025

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Highest Development Status : Discovery Platform

                            Sponsor : AstraZeneca

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Alteogen

                            South Korea arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Alteogen

                            South Korea arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Trastuzumab Deruxtecan

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Sponsor : Daiichi Sankyo

                            Deal Size : $300.0 million

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Alteogen Signs Deal to Enable Subcutaneous ENHERTU® via Hybrozyme™ Tech

                            Details : Daiichi will acquire worldwide rights to use ALT-B4, Alteogen's novel hyaluronidase, to develop and commercialize a subcutaneous version of Enhertu (trastuzumab deruxtecan), a HER2 directed ADC.

                            Product Name : Enhertu

                            Product Type : Antibody-drug Conjugate

                            Upfront Cash : $20.0 million

                            November 10, 2024

                            Lead Product(s) : Trastuzumab Deruxtecan

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Sponsor : Daiichi Sankyo

                            Deal Size : $300.0 million

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Altos Biologics

                            South Korea arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Altos Biologics

                            South Korea arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Aflibercept

                            Therapeutic Area : Ophthalmology

                            Study Phase : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Altos Biologics Files for Approval of Aflibercept Biosimilar

                            Details : ALT-L9 (aflibercept), biosimilar of Eylea, is a recombinant fusion protein which inhibits VEGF A. It is being evaluated in phase 3 clinical studies for the treatment of Neovascular (Wet) AMD.

                            Product Name : Undisclosed

                            Product Type : Protein

                            Upfront Cash : Inapplicable

                            July 01, 2024

                            Lead Product(s) : Aflibercept

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Altos Biologics

                            South Korea arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Altos Biologics

                            South Korea arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Aflibercept

                            Therapeutic Area : Ophthalmology

                            Study Phase : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Altos Biologics, a Subsidiary of Alteogen, Completed Patient Enrollment in Global Phase 3 Clinical Trial of Ey...

                            Details : ALT-L9 (aflibercept) is a vascular endothelial growth factor (VEGF) inhibitor used to treat Neovascular (Wet) Age-Related Macular Degeneration (AMD), various types of macular edema and diabetic retinopathy.

                            Product Name : Undisclosed

                            Product Type : Protein

                            Upfront Cash : Inapplicable

                            February 22, 2023

                            Lead Product(s) : Aflibercept

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Alteogen

                            South Korea arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Alteogen

                            South Korea arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Technology

                            Study Phase : Undisclosed

                            Sponsor : Sandoz B2B

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Alteogen Enters Into an Exclusive License Agreement to Develop and Commercialize Biosimilar Products Enabled b...

                            Details : ALT-B4 is Alteogen’s proprietary human recombinant human hyaluronidase enzyme developed utilizing the Hybrozyme™ technology. ALT-B4 can enable the large volume subcutaneous administration of drugs that are typically administered as an IV infusion.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Undisclosed

                            January 02, 2023

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Technology

                            Highest Development Status : Undisclosed

                            Sponsor : Sandoz B2B

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Alteogen

                            South Korea arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Alteogen

                            South Korea arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ALT-BB4

                            Therapeutic Area : Undisclosed

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Clinical Study of ALT-BB4 to Determine Tolerance, Safety and Pharmacokinetics in Healthy Volunteer

                            Details : ALT-BB4 is a Enzyme drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.

                            Product Name : Undisclosed

                            Product Type : Enzyme

                            Upfront Cash : Inapplicable

                            February 09, 2022

                            Lead Product(s) : ALT-BB4

                            Therapeutic Area : Undisclosed

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Alteogen

                            South Korea arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Alteogen

                            South Korea arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ALT-B4,Undisclosed

                            Therapeutic Area : Oncology

                            Study Phase : Discovery Platform

                            Sponsor : Intas Pharmaceuticals

                            Deal Size : $109.0 million

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Alteogen Enters Into an Exclusive License Agreement With Intas to Develop and Commercialize Two Products Enabl...

                            Details : Under the terms of the agreement, Alteogen has granted worldwide rights, except for a few Asian countries, for Intas to develop two products in combination with ALT-B4.

                            Product Name : Undisclosed

                            Product Type : Enzyme

                            Upfront Cash : $6.0 million

                            January 07, 2021

                            Lead Product(s) : ALT-B4,Undisclosed

                            Therapeutic Area : Oncology

                            Highest Development Status : Discovery Platform

                            Sponsor : Intas Pharmaceuticals

                            Deal Size : $109.0 million

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Alteogen

                            South Korea arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Alteogen

                            South Korea arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ALT-B4

                            Therapeutic Area : Oncology

                            Study Phase : Discovery Platform

                            Sponsor : Undisclosed

                            Deal Size : $3,881.0 million‬

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Alteogen Enters into a Global License Agreement with a Top Ten Pharma

                            Details : Under the terms of the agreement, Alteogen has granted worldwide rights for TTPC to develop multiple products in combination with ALT-B4.

                            Product Name : Undisclosed

                            Product Type : Enzyme

                            Upfront Cash : $16.0 million

                            June 24, 2020

                            Lead Product(s) : ALT-B4

                            Therapeutic Area : Oncology

                            Highest Development Status : Discovery Platform

                            Sponsor : Undisclosed

                            Deal Size : $3,881.0 million‬

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Alteogen

                            South Korea arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Alteogen

                            South Korea arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ALT-P7

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Alteogen Presents the First-in-Human Data on ALT-P7, a HER2-targeting Antibody-Drug Conjugate (ADC) at ASCO 20...

                            Details : This is a FIH clinical trial of ALT-P7, a HER2-targeting ADC, and is a single-group, dose-escalation study designed to determine the maximum tolerated dose (MTD) and evaluate the safety of ALT-P7.

                            Product Name : Undisclosed

                            Product Type : Antibody-drug Conjugate

                            Upfront Cash : Inapplicable

                            May 29, 2020

                            Lead Product(s) : ALT-P7

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth